Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome

Drugs

Volumn 61, Issue 5, 2001, Pages 641-684

  Culy, Christine R ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DIAZIQUONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MAFOSFAMIDE; MELPHALAN; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PERFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

CELL PROTECTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ESOPHAGITIS; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SNEEZING; SOMNOLENCE; VOMITING; XEROSTOMIA;

EID: 0034998360     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161050-00012     Document Type: Review

References (188)

1. 1. Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995 Dec; 50: 1001-31
2. 2. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999 Apr; 26 Suppl. 7: 3-21
3. 3. Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 2000; 16 (4): 237-79
4. 4. DeNeve WJ, Everett CK, Suminski JE, et al. Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 1988 Nov 1; 48: 6002-5
5. 5. Treskes M, van der Vigh WJF. WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 1993 Nov; 33: 93-106
6. 6. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, et al. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 1992 Mar 3; 43: 1013-9
7. 7. Romano MF, Lamberti A, Bisogni R, et al. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood 1999 Dec 15; 94 (12): 4060-6
8. 8. Ramakrishnan N, Catravas GN. N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J Immunol 1992 Mar 15; 148 (6): 1817-21
9. 9. Provinciali M, Ciavattini A, Di Stefano G, et al. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 1999: 64: 1525-32
10. 10. Liu S-C, Murley JS, Woloschak G, et al. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 1997 Dec; 18: 2457-9
11. 11. Woloschak GE, Pauneski T, Chang-Liu CM, et al. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res 1995 Nov 1; 55 (21): 4788-92
12. 12. North S, El-Ghissassi F, Pluquet O, et al. The cytoprotective aminothiol WR1065 activates p21 waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000 Feb 24; 19 (9): 1206-14
13. 13. Murley JS, Grdina DJ. The effects of cycloheximide and WR1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis 1995 Nov; 16 (11): 2699-705
14. 14. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988 Jul 1; 48: 3634-40
15. 15. Kataoka Y, Murley JS, Patel R, et al. Cytoprotection by WR1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int J Radiat Biol 2000 May; 76 (5): 633-9
16. 16. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer A 1994; 30A (2): 183-7
17. 17. Wasserman TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981; 4 (1): 3-6
18. 18. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982 Nov; 42 (11): 4330-1
19. 19. Yuhas JM. Differential protection of normal tissue and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979 Jun; 63 (6): 971-6
20. 20. Green D, Bensely D, Schein P. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Cancer Res 1994 Feb 1; 54: 738-41
21. 21. van Laar JA, van der Wilt CL, Treskes M. et al. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1992; 31: 97-102
22. 22. Millar JL, McElwain TJ, Clutterbuck RD, et al. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 1982 Jun; 5 (3): 321-8
23. 23. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988 Jun 1; 61: 2192-5
24. 24. Kyoizumi S, McCune JM, Namikawa R. Direct evaluation of radiation damage in human hematopoietic progenitor cells in vivo. Radiat Res 1994 Jan; 137: 76-83
25. 25. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and pre-irradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 1992; 22 (4): 773-9
26. 26. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994 Jun 1; 83: 3132-7
27. 27. Douay L, Hu C, Giarratana M-C, et al. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer A 1995; 31A Suppl. 1: S14-6
28. 28. Douay L, Hu C, Giarratana M-C, et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging [abstract]. Blood 1995; 86: 2849-55
29. 29. Pierelli L, Scambia G, Fattorossi A, et al. In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue. Br J Cancer 1998 Oct; 78 (8): 1024-9
30. 30. Taylor CW, Wang LM, List AF, et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer A 1997 Sep; 33: 1693-8
31. 31. List AF, Heaton R, Glinsmann-Gibson B, et al. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996 Aug; 23 Suppl. 8: 58-63
32. 32. An J, Flomenberg N, Capizzi RL. Amifostine protects normal hematopoietic progenitors while sesitizing BCR/ABL+ myeloid leukemic progenitors to the cytotoxic effect of nitrogen mustard [abstract no. 2277]. Blood 1999; 94 Suppl. 1 (Pt 2)
33. 33. Meagher RC, Rothman SA, Paul P, et al. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment. Cancer Res 1989 Jul 1; 49: 3637-41
34. 34. Yuhas JM, Spellman JM, Jordan SW, et al. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980; 42: 574-85
35. 35. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dicholorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980 Jan; 64 (1): 57-64
36. 36. Treskes M, Holwerda U, Nijtmans LGJ, et al. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother Pharmacol 1992 Apr; 29: 467-70
37. 37. Treskes M, Boven E, Holwerda V, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992 Apr 15; 52: 2257-60
38. 38. Weichert-Jacobsen KJ, Bannowski A, Küppers F, et al. Direct amifostine effect on renal tubule cells in rats. Cancer Res 1999 Jul 15; 59: 3451-3
39. 39. Williams MV, Denekamp J. Modification of the radiation response of the mouse kidney by misonidazole and WR-2721. Int J Radiat Oncol Biol Phys 1983 Nov; 9: 1731-6
40. 40. Verstappen CC, Geldof AA, Postma TJ, et al. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065. J Neurooncol 1999 Aug; 44 (1): 1-5
41. 41. Muller LJ, Moorer-van Delft CM, Treskes M, et al. Properties of WR2721 (Ethiofos) as modulator of cisplatin-induced neurotoxicity studied at the ultrastructural level in the pond snail Lymnaea-stagnalis. Int J Oncol 1993 Apr; 2: 701-10
42. 42. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR1065, in vitro. Eur J Cancer A 1996; 32A Suppl. 4: S21-5
43. 43. Nazeyrollas P, Prévost A, Baccard N. et al. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999 Mar; 43: 227-32
44. 44. Nici L, Calabresi P. Amifostine modulation of bleomycin-induced lung injury in rodents. Semin Oncol 1999 Apr; 26 Suppl. 7: 28-33
45. 45. Allalunis-Turner MJ, Siemann DW. Modification of cyclophosphamide-induced pulmonary toxicity in normal mice. NCI Monogr 1988; 6: 51-3
46. 46. Travis EL, De Luca AM. Protection of mouse lung by WR-2721 after fractionated doses of irradiation. Int J Radiat Oncol Biol Phys 1985 Mar; 11: 521-6
47. 47. Down JD, Laurent GJ, McAnulty RJ, et al. Oxygen-dependent protection of radiation lung damage in mice by WR 2721. Int J Radiat Biol Relat Stud Phys Chem Med 1984 Nov; 46: 597-607
48. 48. Menard TW, Izutsu KT, Ensign WY, et al. Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: effect on gland weight and secretion at 8-10 days post irradiation. Int J Radiat Oncol Biol Phys 1984 Sep; 10: 1555-9
49. 49. Sodicoff M, Conger AD, Trepper P, et al. Short-term radioprotective effects of WR-2721 on the rat paratoid glands. Radiat Res 1978 Aug: 75 (2): 317-26
50. 50. Sodicoff M, Conger AD, Pratt NE, et al. Radioprotection by WR-2721 against long-term chronic damage to the rat paratoid gland. Radiat Res 1978 Oct; 76 (1): 172-9
51. 51. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit model. Int J Radiat Oncol Biol Phys 1999 Aug; 45 (1): 181-6
52. 52. Dendale R, Bourhis J, Diawara O, et al. Effect of systemic and topical administration of amifostine on radiation-induced mucositis in mice [abstract]. 33rd Proc Am Soc Clin Oncol; 1997 May 17; 16: Denver (CO), 64a
53. 53. Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300-7
54. 54. Patriarca F. Amifostine pretreatment for protection against melphalan + busulfan-induced toxicity in high-dose therapy for multiple myeloma patients [abstract no. 5034]. Blood 1999; 94 Suppl. 1 (Pt 2): 404b
55. 55. Olivieri A, Poloni A, Capelli D. et al. Effect of amifostine on mucositis during autologous PBPC transplantation [abstract]. Blood 1998 Nov 15; 92 Suppl. 1 (Pt 1): 275
56. 56. De Souza CA, Santini G, Marino G, et al. Amifostine (WR-2721), a cytoprotective agent in high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Braz J Med Biol Res 2000; 33: 791-8
57. 57. Srivastava A, Nair SC, Srivastava VM, et al. Evaluation of unprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. Bone Marrow Transplant 1999 Mar; 23 (5): 463-7
58. 58. Delaney JP, Bonsack ME, Felemovicius I. Radioprotection of the small rat intestine with topical WR-2721. Cancer 1994 Oct 15; 74: 2379-84
59. 59. Ito H, Meistrich ML, Barkley Jr HT, et al. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. Int J Radiat Oncol Biol Phys 1986 Feb; 12: 211-9
60. 60. France Jr HG, Jirtle RL, Mansbach II CM. Intracolonic WR 2721 protection of the rat colon from acute radiation injury. Gastroenterology 1986 Sep; 91: 644-50
61. 61. Prasanna PGS, Devi PU. Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine. Radiat Res 1993 Jan; 133: 111-5
62. 62. Ito H, Komaki R, Milas L. Protection by WR-2721 against radiation plus cis-diamminedichloroplatinum II caused injury to colonic epithelium in mice. Int J Radiat Oncol Biol Phys 1994 Mar 1; 28: 899-903
63. 63. Wist EA. Effect of the radioprotector WR 2721 on the response of metastatic Lewis lung carcinoma colonies to alkylating agents. Acta Radiol Oncol 1985 May-Jun; 24: 259-62
64. 64. Milas L, Ito H, Hunter N. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide. Cancer Res 1983 Jul; 43: 3050-6
65. 65. Penhaligon M. Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721. Int J Radiat Oncol Biol Phys 1984 Sep; 10: 1541-4
66. 66. Hunter NR, Guttenberger R, Milas L. Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721. Int J Radiat Oncol Biol Phys 1992; 22 (4): 795-8
67. 67. McChesney SL, Gillette EL, Dewhirst MW, et al. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1986 Nov; 12: 1957-63
68. 68. Milas L, Hunter N, Ito H, et al. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys 1984 Jan; 10: 41-8
69. 69. Rasey JS, Krohn KA, Magee S, et al. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor. Radiat Res 1986 Nov; 108: 167-75
70. 70. Stewart FA, Rojas A, Denekamp J. Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments. Int J Radiat Oncol Biol Phys 1983 Apr; 9: 507-13
71. 71. Ribizzi I, Darnowski JW, Goulette FA, et al. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk Res 2000 Jun; 24 (6): 519-25
72. 72. Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 1994 Oct; 21 Suppl. 11: 26-32
73. 73. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997 Nov 1; 90: 3364-9
74. 74. List AF, Talley M, Obregon Y, et al. Combined treatment with amifostine and topotecan: high remitting potential in advanced myelodysplastic syndrome (MDS) [abstract no. 103]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 28a
75. 75. Grossi A, Fabbri A, Santini V, et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 2000 Apr; 85: 367-71
76. 76. Galanopoulos E, Kritikou-Griva J, Gligori J, et al. Treatment of myelodysplastic syndrome with amifostine and its effect on hematopoiesis [abstract no. 1367]. Blood 1999; 94 Suppl. 1 (Pt 1): 306a
77. 77. Milas L, Hunter N, Stephens LC, et al. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1984 Dec; 44 (12 Pt 1): 5567-9
78. 78. Grdina DJ, Carnes BA, Grahn D, et al. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1991 Aug 15; 51: 4125-30
79. 79. Carnes BA, Grdina DJ. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis. Int J Radiat Biol 1992 May; 61: 567-76
80. 80. Grdina DJ, Peraino C, Carnes BA, et al. Protective effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid against induction of altered hepatocyte foci in rats treated once with γ-radiation within one day after birth. Cancer Res 1985 Nov; 45 (11 Pt 1): 5379-81
81. 60Co γ-ray irradiation. Carcinogenesis 1986; 7: 665-8
82. 82. Nagy B, Dale PJ, Grdina DJ. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino ethanethiol. Cancer Res 1986 Mar; 46 (3). 1132-1135
83. 83. Nagy B, Grdina DJ. Protective effects of 2-[(aminopropyl) amino]ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 1986 Aug; 12 (8): 1475-8
84. 84. Kataoka Y, Perrin J, Hunter N, et al. Antimutagenic effects of amifostine: clinical implications. Semin Oncol 1996 Aug; 23 Suppl. 8: 53-7
85. 85. Grdina DJ, Kataoka Y, Basic I, et al. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis 1992 May; 13: 811-4
86. 60Co γ-rays in mice. Int J Radiat Biol 1992 Mar; 61: 387-92
87. 87. Newton GL, Aguilera JA, Ward JF, et al. Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei. Radiat Res 1996 Sep; 146 (3): 298-305
88. 88. Grdina DJ, Shigematsu N, Dale P, et al. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995 Apr; 16: 767-74
89. 89. Vaughan ATM, Grdina DJ, Meechan PJ, et al. Conformational changes in chromatin structure induced by the radioprotective aminothiol, WR-1065. Br J Cancer 1989 Dec; 60 (6): 893-6
90. 90. Savoye C, Swenberg C, Hugot S, et al. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol 1997 Feb; 71: 193-202
91. 91. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol 1996 Aug; 23 Suppl. 8: 18-22
92. 92. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986 Aug; 12: 1501-4
93. 93. Shaw LM, Glover D, Turrisi A, et al. Pharmacokinetics of WR-2721. Pharmacol Ther 1988; 39: 195-201
94. 94. Shaw L, Bonner H, Nakashima H, et al. Pharmacokinetics of amifostine in cancer patients: evidence for saturable metabolism [abstract]. Proc Am Soc Clin Oncol; 1994 Mar; 13: 144
95. 95. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol 1999 Apr; 26 Suppl. 7: 34-6
96. 96. Korst AEC, Eeltink CM, Vermorken JB. Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer A 1997 Aug; 33: 1425-9
97. 97. Utley JF, Seaver N, Newton GL, et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radial Oncol Biol Phys 1984 Sep; 10: 1525-8
98. 98. Shaw L, Brown W, Schein P, et al. A phase I study comparing the relative bioavailability of intravenous and subcutaneous administration of amifostine (Ethyol) [abstract]. 33rd Proc Am Soc Clin Oncol; 1997 May 17; 16: Dallas (TX), 250a
99. 99. Korst AEC, van der Sterre MLT, Gall HE, et al. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998 Feb; 4: 331-6
100. 100. Korst AEC, van der Sterre MLT, Eeltink CM, et al. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clin Cancer Res 1997 May; 3: 697-703
101. 101. Schüller J, Czejka M, Krexner E, et al. Amifostine (AMI) differently influences pharmacokinetics (PK) of selected cystostatic agents (CY) [abstract]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S245
102. 102. Martens-Lobenhoffer J, Fuhlroth J, Ridwelski K. Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. Int J Clin Pharmacol Ther 2000 Jan; 38: 41-4
103. 103. Eickhoff C, Eickhoff E, Regazzi M, et al. Influence of amifostine on the pharmacokinetics of anticancer drugs [abstract]. Pharm World Sci 2000 Feb; 22: A11
104. 104. Kletzl H, Czejka MJ, Schüller J, et al. In-vitro and in-vivo drug interaction between doxorubicin (DOXO), epirubicin (EPI) and the cytoprotective agent amifostine (AMI) [abstract]. 8th International Congress on Anticancer Treatment; 1998 Feb 3; Paris, 219
105. 105. Alza Pharmaceuticals. Ethyol (amifostine) for injection product information. Available from: URL: http://www.ethyol.com/ pros/pi.htm [Accessed 2000 Dec 11]
106. 106. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996 Jul; 14: 2101-12
107. 107. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000 Oct 1; 18 (19): 3339-45
108. 108. Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer [abstract no. 18]. Int J Radiat Oncol Biol Phys 1999; 45 Suppl. 3: 154
109. 109. Souquet PJ, Fourniol A, Vergnenegre A, et al. Randomised phase III trial of MIP regimen (mitomycin-ifosfamide-platine) with or without amifostine (Ethyol) in advanced non-small cell lung cancer (NSCLC) [abstract no. 1882]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 488a
110. 110. Avilés A, Díaz-Maqueo JC, Talavera A, et al. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer A 1997 Jul; 33: 1323-5
111. 111. Betticher DC, Anderson H, Ranson M, et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer 1995 Dec; 72: 1551-5
112. 112. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997 Sep 15; 80: 1134-40
113. 113. Glick JH, Glover D, Weiler C, et al. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984 Sep; 10: 1777-80
114. 114. Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986 Apr; 4: 584-8
115. 115. Hartmann JT, Jnop S, Fels LM, et al. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 2000 Jan; 11: 1-6
116. 116. Heidenreich A, Marx FJ, Peters HJ. Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer. Urologe A 1999; 38 (6): 586-91
117. 117. Johnson PWM, Muers MF, Peake MD, et al. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. Br J Cancer 2001; 84 (1): 19-24
118. 118. Petrilli AS, Oliveira VC, Ginani R, et al. Amifostine (AM) in pediatric osteosarcoma (OS). 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 560a
119. 119. Planting AST, Catimel G, de Mulder PHM, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999 Jun; 10: 693-700
120. 120. Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. Int J Colorectal Dis 1999 Apr; 14: 128-30
121. 121. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999 Oct; 17: 3038-47
122. 122. Gold MA, Walker JL, Berek JS, et al. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase II trial in patients with advanced gynecologic malignancies [abstract]. Gynecol Oncol 2000 Feb; 76: 279
123. 123. Jost LM, Michel G, Dunkel-de Raad S, et al. Value of amifostine-cytoprotection in cisplatin and fluorouracil (5-FU) chemotherapy in head and neck cancer (HNCA). A randomized open-label trial [abstract no. 1515]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 392a
124. 124. Poplin EA, LoRusso P, Lokich JJ, et al. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994 Feb; 33: 415-9
125. 125. Stupp R, Priscoveanu A, Mingrone W, et al. Decreased toxicity and excellent tolerability, when amifostine is added to standard cisplatin and 5-fluorouracil chemotherapy for head and neck cancer. Schweiz Kerbs Bull 1999 Dec; 19: 166-9
126. 126. British Medical Association RPS of GB. Chapter 8: Malignant disease and immunosuppression (Side effects of cytotoxic drugs). British National Formulary, 2000. 39th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2000: 389
127. 127. Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 1996 Aug; 23 Suppl. 8: 83-9
128. 128. Anderson H, Mercer V, Thatcher N. A phase III randomised trial of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small cell lung cancer (NSCLC) [abstract]. 34th Proc Am Soc Clin Oncol; 1998 May 16; 17: Los Angeles (CA), 465a
129. 129. Cisplatin product summary. ABPI conpendium of data sheets and summaries of product characteristics; Datapharm Publications, 2000
130. 130. Oster W, Scheffler BS, Habboubi N, et al. Selective nephroprotection by ethyol (amifostine) from cumulative cisplatin toxicity [abstract]. Onkologie 1995 Oct; 18 Suppl. 2: 183
131. 131. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996 Jun; 14: 1913-21
132. 132. DiPaola RS, Schuchter L. Neurologic protection by amifostine. Semin Oncol 1999 Apr; 26 Suppl. 7: 82-8
133. 133. DiPaola R, Goodin S, Rodriguez R, et al. Amifostine and dose intense paclitaxel in patients with advanced malignancies [abstract]. 33rd Proc Am Soc Clin Oncol; 1997 May 17; 16: Denver (CO), 235a
134. 134. Mitchell RB, Campbell Jr WW. A phase II trial of amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small cell lung cancer [abstract no. 2322]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 601a
135. 135. Srimuninnimit V. A phase II study with carboplatin and paclitaxel plus amifostine in the treatment of advanced non-small cell lung cancer: preliminary report [abstract]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 524a
136. 136. Ndubisi BU, Guthrie TH, Benrubi GI, et al. A phase II open-label study to evaluate the use of amifostine (ethyol) in reversing chemotherapy-induced peripheral neuropathy (PN) in cancer patients: preliminary findings [abstract no. 2326]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 602a
137. 137. Hartmann J, von Vangerow A, Fels LM, et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation. Br J Cancer 2001; 84 (3): 313-20
138. 138. Chauncey TR, Gooley TA, Lloid ME, et al. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol 2000 Aug; 23; 406-11
139. 139. Balzarotti M, Grisanti S, Granzow K, et al. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin Oncol 1999 Apr; 26 Suppl. 7: 66-71
140. 140. Cagnoni PJ, Jones RB, Bearman SI, et al. Use of amifostine in bone marrow purging. Semin Oncol 1996 Aug; 23 Suppl. 8: 44-8
141. 141. Rudat V, Meyer J, Momm F, et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 2000; 48 (5): 1339-43
142. 142. Bohuslavizki KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998 Nov; 16: 3542-9
143. 143. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell cancer. Int J Radiat Oncol Biol Phys 2000; 46 (5): 1105-8
144. 144. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000 Jun; 18: 2226-33
145. 145. Schönekäs KG, Wagner W, Prott FJ. Amifostine: a radioprotector in locally advanced head and neck tumors. Strahlenther Onkol 1999 Nov; 175 Suppl. 4: 27-9
146. 146. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992 Jun 1; 69: 2820-5
147. 147. Montana GS, Anscher MS, Mansbach IC, et al. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis: a phase I/II trial. Cancer 1992 Jun 1; 69: 2826-30
148. 148. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999 Nov; 21: 367-87
149. 149. Antonadou D, Pepelassi E, Synodinou M, et al. The prophylactic use of amifostine in the prevention of chemoradiation induced mucositis and xerostomia in head and neck cancer. Int J Radiat Oncol Biol Phys 1998; 42 Suppl. 1: 224
150. 150. Büntzel J, Schuth J, Küttner K, et al. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998 Mar; 6: 155-60
151. 151. Antonadou D, Synodinou M, Boufi M, et al. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage non small cell lung cancer [abstract no. 1960]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 501a
152. 152. Werner-Wasik M, Friedland D, Axelrod R, et al. Amifostine reduces severe esophagitis during concurrent chemotherapy with weekly paclitaxel and thoracic irradiation in patients with locally advanced non-small cell lung cancer [abstract no. 2267]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 587a
153. 153. Tan W, Tin-U C, Zellars R, et al. Phase I study of weekly paclitaxel in combination with daily cisplatin and radiation in locally advanced head and neck (H/N), locally advanced non-small cell lung carcinoma (NSCL), and esophageal carcinoma [abstract no. 1582]. 35th Proc Am Soc Clin Oncol; 1999 May 15; 18: Atlanta (GA), 409a
154. 154. Rosen FR, Chung TD, Portugal B, et al. Amifostine (A), concomitant cisplatin (C), paclitaxel (P) and re-irradiation (RI) in recurrent head and neck cancer (HNC) [abstract no. 1686]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 427a
155. 155. Amrein PC, McIntyre J, Colevas AD, et al. A phase I trial of concurrent taxol and Bid radiotherapy with or without ethyol in patients with advanced squamous cell carcinoma of the head and neck [abstract no. 1651]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 418a
156. 156. Jaremtchuk V, Zarba JJ, Keropian M, et al. Phase I study of gemcitabine combined with radiotherapy with or without amifostine in patients with locally advanced head and neck cancer [abstract no. 1674]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 424a
157. 157. Yavuz AA, Aydin F, Yavuz NM, et al. A phase I trial of radiation therapy (RT) plus concurrent fixed dose amifostine (AMI) with escalating doses of twice-weekly gemcitabine (TW-GEM) in advanced pancreatic cancer [abstract no. 1105]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 283a
158. 158. Trog D, Bank P, Wendt TG, et al. Daily amifostine given concomitantly to chemoradiation in head and neck cancer; a pilot study. Strahlenther Onkol 1999; 175 (9): 444-9
159. 159. Büntzel J, Glatzel M, Weinaug R, et al. Intensified radiochemotherapy with amifostine in head and neck cancer [abstract]. Ann Oncol 1998; 9 Suppl. 4: 75-6
160. 160. Gaman G, Gaman A. Amifostine in the treatment of myelodysplastic syndrome [abstract]. Hematol J 2000 Jun; 1 Suppl. 1: 83
161. 161. Bowen DT, Denzlinger C, Brugger W, et al. Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic patients. Br J Haematol 1998 Dec; 103 (3): 785-7
162. 162. Brasfield FM, Heaton R, Glinsmann-Gibson B, et al. Phase I/II trial of subcutaneous amifostine in patients with myelodysplastic syndrome (MDS) [abstract no. 13]. 34th Proc Am Soc Clin Oncol; 1998 May 16; 17: Los Angeles (CA), 4a
163. 163. deCastro CM, Gockerman JP, Moore JO, et al. Treatment of myelodysplastic syndrome with amifostine [abstract]. Blood 1998 Nov 15; Suppl. 1 (Pt 2): 251b
164. 164. Hofmann WK, Seipelt G, Ottmann OG, et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor a levels. Ann Hematol 2000; 79: 255-8
165. 165. Kempin S, Sirott M, Cecchi G, et al. Phase II study of amifostine for the treatment of the myelodysplastic syndrome (MDS) [abstract no. 108]. 34th Proc Am Soc Clin Oncol; 1998 May 16; 17: Los Angeles (CA), 28a
166. 166. List AF, Holmes H, Greenberg PL, et al. Phase II study of amifostine in patients with myelodysplastic syndromes (MDS) [abstract no. 1362]. Blood 1999; 94 Suppl. 1 (Pt 2)
167. 167. Kagmakis P, Potamousi P, Mpisbiroula A, et al. The role of amifostine in myelodysplastic syndromes [abstract]. 9th International Congress on Anticancer Treatment; 1999 Feb 2: Paris, 249
168. 168. Raza A, Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000 Mar 1; 95: 1580-7
169. 169. Wadler S, Haynes H, Beitler JJ, et al. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. J Clin Oncol 1993 Aug; 11: 1517-22
170. 170. Glover D, Riley L, Carmichael K, et al. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med 1983 Nov 10; 309: 1137-41
171. 171. Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino) ethylphosphorothioic acid]. Cancer Treat Rep 1986 Dec; 70: 1389-93
172. 172. Fouladi M, Koren G, Greenberg ML, et al. Safety and monitoring guidelines of amifostine in the pediatric population: results of a phase I/II trial of ICE with amifostine [abstract]. J Clin Pharmacol 1998 Sep; 38: 842
173. 173. Kavan P, Kabickova E, Stankova J, et al. Protection of normal tissue by amifostine (Ethyol) from the cytotoxic effects of megatherapy with autologous stem cell rescue in children [abstract]. Bone Marrow Transplant 1999 Mar; 23 Suppl. 1: 74
174. 174. Borst JD, Csáki C, Ferencz T, et al. Safety and efficacy of amifostine in children to prevent myelotoxicity of high-dose carboplatin: preliminary results of a cooperative phase I-II clinical trial [abstract]. 33rd Proc Am Soc Clin Oncol; 1997 May 17; 16: Denver (CO), 523a
175. 175. Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995 Sep 15; 55: 4069-72
176. 176. Spath-Schwalbe E, Lange C, Genvresse I, et al. The cytoprotective agent amifostine is well tolerated by patients ≥ 70 years [abstract no. 2428]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 617a
177. 177. Bennett CL, Golub R, Calhoun E, et al. Cost-utility assessment of amifostine in first-line therapy for ovarian cancer [abstract]. Int J Gynecol Cancer 1998; 8: 64-72
178. 178. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Care Cancer 1997 Nov; 5: 489-99
179. 179. Domagk KR, Werner E, Buntzel J, et al. Pharmacoeconomic study in patients with head and neck cancer (HNC) receiving radiochemotherapy [abstract]. 36th Proc Am Soc Clin Oncol; 2000 May 20; 19: New Orleans (LA), 441a
180. 180. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999 Apr; 26 Suppl. 7: 72-81
181. 181. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999 Oct; 17: 3333-55
182. 182. Alberts DS. Protection by amifostine of cyclophosphamide-induced myelosuppression. Semin Oncol 1999 Apr; 26 Suppl. 7: 37-40
183. 183. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 Suppl. 1: S87-92
184. 184. Selvaggi G, Belani CP. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Semin Oncol 1999 Apr; 26 Suppl. 7: 51-60
185. 185. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997 Aug; 15 (8): 2996-3018
186. 186. Alberts DS. Future directions in gynecologic cancer. Semin Oncol 1999 Apr; 26 Suppl. 7: 125-8
187. 187. Schiller JH. Future directions in non-small cell lung cancer. Semin Oncol 1999 Apr; 26 Suppl. 7: 120-4
188. 188. NCCN practice guidelines for the myelodysplastic syndromes. Oncology 1998 Nov; 12 (11A): 53-80